Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Nasdaq

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Aug 17, 2022 2:59pm

108 Views

Post# 34902924

RE:RE:RE:RE:Nasdaq

The difference between the exercise price if the option and the market price on the date of the exercise is a capital gain 50% of which is added to your iincome
Exerciding a warrant to acquire dtock does not create a tax liability imo until you sell the stock and the capital gain is the difference between the sale price snd the exercise price of the warrants
I am not s tax specialist .......

Lee430 wrote: Palinc2000, Do you know if there a tax advatage to exercising grants at a low SP? Not necessarily looking for a conspiracy just curious.

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks